Its CYB003 is a deuterated psiloCybin analog that treats major depressive disorder and alcohol use disorder ... This is based on a combination of machine learning and a proprietary algorithm to ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

The most-read articles addressing mental health in 2024 spanned therapeutic advancements, research discoveries, and insight ...

In past trials, ketamine intravenous treatment has shown promise, with 64% of depression patients in trials experiencing ...

Many treatment options are available for managing neurological disorders, offering hope and reassurance. From medications, therapies, and surgical intervention to lifestyle changes, numerous ways ...

For others, they may need more treatment. Overall, the program has had high response rates among Ascension patients. TMS is insurance covered but providers will likely require step therapy as the ...

CMS has balked at covering vagus nerve stimulation for treatment-resistant depression. Positive results from an ...

In a recent study, transcranial magnetic stimulation was found to be more effective than switching to a new medication for ...

At 14, she says that she was aware of eating disorders ... treatment centers trying to recover from the eating disorder. "It's just taken my life away pretty much," she reflects. Asked why ...

While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment ... prescribed to treat depression and anxiety ...

The elimination of these cells, known as reservoirs, would prevent the rebound of viremia observed in infected people who are on long-term treatment. Eradicating these reservoirs remains an ...